Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature

The purpose of this review is to acquaint the audience with the benefits of infantile hemangioma  (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no system...

Full description

Saved in:
Bibliographic Details
Main Authors: O.V. Bogomolets, O.V. Selyuk, K.P. Bogomolets, S.O. Bogomolets-Sheremetieva
Format: Article
Language:English
Published: Group of Companies Med Expert, LLC 2023-12-01
Series:Сучасна педіатрія: Україна
Subjects:
Online Access:http://mpu.med-expert.com.ua/article/view/299678
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841525014372810752
author O.V. Bogomolets
O.V. Selyuk
K.P. Bogomolets
S.O. Bogomolets-Sheremetieva
author_facet O.V. Bogomolets
O.V. Selyuk
K.P. Bogomolets
S.O. Bogomolets-Sheremetieva
author_sort O.V. Bogomolets
collection DOAJ
description The purpose of this review is to acquaint the audience with the benefits of infantile hemangioma  (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no systemic side effects. We aimed to analyze the effectiveness and limitations of the use of local β-blockers, to show the possibility and expediency of IH management in pediatric practice, and to demonstrate that the goal of therapy is not the treatment of complications, but the prevention of their occurrence and complete resolution of the hemangioma without surgical intervention. The use of topical β-blockers, such as timolol gel or solution, provides a non-surgical, non-invasive treatment option for IH, minimizing the systemic exposure and possible side effects associated with oral β-blockers. Local treatment is best started before the age of 2 months - at an early stage, when IHs are small in size, potentially preventing the need for more invasive treatment methods. Topical use is associated with a lower risk of systemic side effects, such as hypotension or bradycardia, that can occur with oral β-blockers. Topical treatment can be applied at home, which can be more convenient for parents and caregivers, and also increases the opportunity for treatment and follow-up by pediatricians. In case of natural disasters or military operations, treatment can be done remotely using teledermatology. The effectiveness of local β-blockers mostly depends on the age at which treatment was started: the earlier it was started, the higher the effectiveness. Treatment of complicated IH with deep soft tissue, mucosal, or airway involvement usually requires a combination of systemic propranolol and topical β-blockers or other interventions such as laser therapy. The choice of treatment should be selected individually according to the degree of risk of IH, its size, localization, child's age, weight, and other parameters in each clinical case. β-adrenoblockers are the most modern, effective, non-surgical, and safe method of treating IH, they can be used both for systemic and local application. IH can be successfully treated by pediatricians and dermatologists. No conflict of interests was declared by the authors.
format Article
id doaj-art-d5619251539144218c93cab0f6b115f7
institution Kabale University
issn 2663-7553
2706-6134
language English
publishDate 2023-12-01
publisher Group of Companies Med Expert, LLC
record_format Article
series Сучасна педіатрія: Україна
spelling doaj-art-d5619251539144218c93cab0f6b115f72025-01-17T20:34:54ZengGroup of Companies Med Expert, LLCСучасна педіатрія: Україна2663-75532706-61342023-12-018(136)677810.15574/SP.2023.136.67338034Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literatureO.V. Bogomolets0https://orcid.org/0000-0001-7869-8443O.V. Selyuk1https://orcid.org/0000-0001-9597-1165K.P. Bogomolets2S.O. Bogomolets-Sheremetieva3Ukrainian Military Medical Academy, KyivUkrainian Military Medical Academy, KyivDr. Bogomolets’ Institute of Dermatology and Cosmetology, Kyiv, UkraineDr. Bogomolets’ Institute of Dermatology and Cosmetology, Kyiv, UkraineThe purpose of this review is to acquaint the audience with the benefits of infantile hemangioma  (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no systemic side effects. We aimed to analyze the effectiveness and limitations of the use of local β-blockers, to show the possibility and expediency of IH management in pediatric practice, and to demonstrate that the goal of therapy is not the treatment of complications, but the prevention of their occurrence and complete resolution of the hemangioma without surgical intervention. The use of topical β-blockers, such as timolol gel or solution, provides a non-surgical, non-invasive treatment option for IH, minimizing the systemic exposure and possible side effects associated with oral β-blockers. Local treatment is best started before the age of 2 months - at an early stage, when IHs are small in size, potentially preventing the need for more invasive treatment methods. Topical use is associated with a lower risk of systemic side effects, such as hypotension or bradycardia, that can occur with oral β-blockers. Topical treatment can be applied at home, which can be more convenient for parents and caregivers, and also increases the opportunity for treatment and follow-up by pediatricians. In case of natural disasters or military operations, treatment can be done remotely using teledermatology. The effectiveness of local β-blockers mostly depends on the age at which treatment was started: the earlier it was started, the higher the effectiveness. Treatment of complicated IH with deep soft tissue, mucosal, or airway involvement usually requires a combination of systemic propranolol and topical β-blockers or other interventions such as laser therapy. The choice of treatment should be selected individually according to the degree of risk of IH, its size, localization, child's age, weight, and other parameters in each clinical case. β-adrenoblockers are the most modern, effective, non-surgical, and safe method of treating IH, they can be used both for systemic and local application. IH can be successfully treated by pediatricians and dermatologists. No conflict of interests was declared by the authors.http://mpu.med-expert.com.ua/article/view/299678infantile hemangiomahemangioma treatmentlocal β-blockerstimolol
spellingShingle O.V. Bogomolets
O.V. Selyuk
K.P. Bogomolets
S.O. Bogomolets-Sheremetieva
Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
Сучасна педіатрія: Україна
infantile hemangioma
hemangioma treatment
local β-blockers
timolol
title Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
title_full Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
title_fullStr Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
title_full_unstemmed Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
title_short Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
title_sort treatment of infantile hemangioma with topical β blockers in pediatric practice a review of the literature
topic infantile hemangioma
hemangioma treatment
local β-blockers
timolol
url http://mpu.med-expert.com.ua/article/view/299678
work_keys_str_mv AT ovbogomolets treatmentofinfantilehemangiomawithtopicalbblockersinpediatricpracticeareviewoftheliterature
AT ovselyuk treatmentofinfantilehemangiomawithtopicalbblockersinpediatricpracticeareviewoftheliterature
AT kpbogomolets treatmentofinfantilehemangiomawithtopicalbblockersinpediatricpracticeareviewoftheliterature
AT sobogomoletssheremetieva treatmentofinfantilehemangiomawithtopicalbblockersinpediatricpracticeareviewoftheliterature